Group 1: Financing and Investment - ShunJing Pharmaceutical has completed a 300 million RMB Series A financing round, led by multiple investment firms including Songhe Fund and Dacheng Fund [1] - The funds will primarily be used to accelerate the Phase II clinical trials of SGC001, a novel antibody drug for acute myocardial infarction, and other core pipeline IND applications and clinical research [1] - Horizon Robotics has announced a successful 100 million USD Series A financing round, attracting numerous domestic and international investors [2] Group 2: Product Development and Innovation - ShunJing Pharmaceutical focuses on developing first-in-class (FIC) and best-in-class (BIC) drugs, with SGC001 being the fastest in development, having received IND approval from both the FDA and the National Medical Products Administration [1] - The company aims to enhance its strategic layout in the biopharmaceutical industry, aligning with China's 14th Five-Year Plan for biopharmaceutical development [1] - Horizon Robotics has built a complete product system covering chips, algorithms, and software to meet the diverse needs of intelligent robots across various sectors [3] Group 3: Market Expansion and Ecosystem - ShunJing Pharmaceutical's funding is expected to deepen its strategic layout and enhance its long-term operational development [1] - Horizon Robotics is expanding its developer ecosystem, empowering over 200 small and medium-sized creators and incubating nearly 100 new types of intelligent robots [5] - The company has established partnerships with over 200 universities to cultivate talent in the field of intelligent robotics [6] Group 4: Industry Trends and Future Outlook - The financing activities reflect a growing interest in the biopharmaceutical and intelligent robotics sectors, indicating a robust investment climate [2][4] - Companies are increasingly focusing on integrating innovative technologies and expanding their product offerings to capture larger market shares [2][5] - The advancements in intelligent robotics and biopharmaceuticals are expected to contribute significantly to the overall growth of the respective industries in the coming years [1][3]

Core Viewpoint - Wuxi Guangwei Semiconductor Materials Co., Ltd. has successfully achieved mass production of ultra-pure quartz sand, marking a significant step in breaking the monopoly of international giants and promoting the domestic substitution process in China's semiconductor materials industry [1][3]. Group 1: Company Overview - Wuxi Guangwei Semiconductor Materials Co., Ltd. was established in April 2024 and is located at 90 Ximei Road, Meicun Street, Xinwu District [3]. - The company focuses on the production and sales of ultra-pure synthetic quartz sand, utilizing advanced technology introduced through international cooperation [3]. Group 2: Project Details - The total investment for the ultra-pure quartz sand project is 200 million yuan, with plans to build three production lines starting construction in July 2024 and the first line expected to be operational by May 2025 [3]. - The initial annual production capacity is projected to be 700 tons, generating sales of 300 million yuan, with the overall project expected to increase annual production to 2,700 tons and sales exceeding 900 million yuan [3]. Group 3: Industry Impact - Ultra-pure quartz sand is a critical foundational material for national strategic emerging industries, known for its high-temperature resistance, corrosion resistance, low thermal expansion, high insulation, and transparency [3]. - The demand for ultra-pure quartz sand is rapidly increasing, particularly in aerospace, military, electronic information, and optical communication sectors [3]. - Previously, this material was exclusively supplied by Mitsubishi Chemical, but Wuxi Guangwei's successful mass production represents a breakthrough in domestic production and market entry, aiding in reducing reliance on imports and achieving "domestic substitution" [3].

中金研究 近年来我国在关键材料国产化上取得明显进展。我们认为在国家各项政策的支持下，中国逐步在诸多先进应用场景中占主导地位，关键材料的国产化 将进入一个加速阶段。在研发创新方面领先的中国化工优秀企业有望迎来新的成长机遇。 点击小程序查看报告原文 Abstract 中国关键材料的国产化替代进程亟待加速。 材料是科学规律在物质世界的映射。"一代材料，一代装备，一代技术"，从石器时代到信息时代，材料自始 自终都是划分人类文明发展阶段的核心标志。当前全球正面临新一轮的科学技术革命，材料作为先进科学技术的物质载体，其发展将对全球经济、科技、 特种等各个领域发展产生深远影响。此外目前国际形势错综复杂，关键材料的国产化替代，有助于保障供应链安全可控。 近年来我国在关键材料国产化上取得明显进展。 第一、高性能纤维行业取得明显成就。碳纤维、芳纶、超高分子量聚乙烯纤维和连续玄武岩纤维等均达 到国际先进水平。第二、在高性能工程塑料领域，聚苯硫醚（PPS）、聚酰亚胺（PI）、聚醚醚酮（PEEK）、液晶聚合物（LCP）及聚砜（PSF）等均已 国产化。第三、在半导体材料领域也取得了显著的进展。如化学机械抛光液、抛光垫、碳化硅、电子级硫酸 ...

Core Viewpoint - TCL Technology is aggressively expanding its semiconductor display business through significant acquisitions, despite a decline in net profit, indicating a strong commitment to strengthening its core operations in the semiconductor sector [2][3]. Group 1: Acquisition Details - TCL Technology announced the acquisition of 21.53% of Shenzhen Huaxing Semiconductor for 11.562 billion yuan, using a combination of cash (7.203 billion yuan) and shares (4.359 billion yuan) [2]. - Post-acquisition, TCL's stake in Shenzhen Huaxing Semiconductor will increase from 62.68% to 84.21%, enhancing its control over this core asset [2]. - This acquisition marks TCL's second major acquisition within six months, following a 10.8 billion yuan purchase of LG Display's Guangzhou LCD panel factory to expand capacity and capture market share vacated by Korean companies [2]. Group 2: Financial Performance - In 2024, TCL Technology's semiconductor display business revenue grew by 24.6% year-on-year to 104.3 billion yuan, achieving a historical high and accounting for over 60% of total revenue [3]. - The net profit for TCL Technology rebounded significantly from a slight loss of 0.07 billion yuan in 2023 to a profit of 6.23 billion yuan in 2024 [3]. - TCL Huaxing, as the core panel business, is the second-largest panel manufacturer in mainland China, with large-size LCD TV panels being its primary strength [3]. Group 3: Business Focus - TCL Technology, founded in 1982, has shifted its focus entirely to the panel industry following a major asset restructuring in 2018, divesting traditional consumer terminal and related businesses [2]. - The company's current business segments include semiconductor displays, new energy photovoltaics, and semiconductor materials [2].

Core Viewpoint - A-shares show resilience amid external market adjustments, indicating a strengthening internal trend supported by recent monetary policy changes and trade negotiations [1][2]. Market Outlook - The current market has largely priced in the tariff events and the first phase of trade negotiations, with a need for additional catalysts to break through March highs [2]. - The extreme drop on April 7 was a one-time reaction to the "equal tariffs" event, and the market has since undergone substantial recovery [2]. - Future challenges to March highs will require new policies, trade negotiation progress, or significant economic indicators [2]. Hot Sectors - June is expected to be driven by event-based thematic trading, with focus on low-position sectors like consumption and pharmaceuticals, as well as adjusted technology growth [3]. - Key areas of interest include: 1. Consumption expansion and domestic demand as a priority for 2025, with expectations for policy support in sectors like dairy, IP consumption, leisure tourism, and medical aesthetics [3]. 2. The trend of robot localization and integration into daily life, with opportunities in sensors, controllers, and dexterous hands [3]. 3. The ongoing trend of semiconductor localization, focusing on semiconductor equipment, wafer manufacturing, materials, and IC design [3]. 4. The military industry is expected to see order recovery by 2025, with signs of bottoming out in various sub-sectors [3]. 5. Innovative drugs are entering a recovery phase after four years of adjustment, with positive net profit growth expected to continue into 2025 [3]. Market Review - A-shares experienced narrow fluctuations with reduced trading volume, while consumption and pharmaceuticals rebounded [4]. - The market showed overall weakness, with 31 primary sectors exhibiting mixed performance, led by textiles, pharmaceuticals, beauty care, environmental protection, and real estate [4].

点击 最 下方 " 推荐"、"赞 "及" 分享 "，"关注"材料汇 添加 小编微信 ，遇见 志同道合 的你 正文 导语 ： 在半导体产业链加速自主可控的浪潮下，科睿迅（上海）材料科技有限公司凭借突破性技术，成 为国内首家实现 CMP 后清洗晶圆刷国产化的企业。其自主研发的半导体级 PVA 清洗刷已通过国内头部 Fab 厂验证，填补了国内空白，为中国半导体材料国产化注入强劲动力。 核心技术突破：打破国际垄断的 "中国刷" 半导体制造中，CMP（化学机械抛光）后的清洗环节直接影响芯片良率，晶圆表面的纳米级污染物可能导 致芯片失效。传统硬质刷辊容易划伤晶圆，且静电吸附会引发二次污染。科睿迅核心产品 —— CMP 后清 洗 刷辊 ，采用国际领先的 PVA（聚乙烯醇）材料技术，通过发泡工艺形成多孔结构，具备三大核心优 势： 高效清洁 ： 吸水后柔软弹性的刷毛可精准移除晶圆表面颗粒污染物，同时避免划痕； 超高洁净度 ： 百级洁净室生产工艺确保刷毛无颗粒脱落，符合半导体行业严苛标准； 2024 年 9 月，科睿迅 南通经开区年产 20 万支半导体用 PVA 清洗刷项目 正式落成，这是国内首条该类 产品量产线，彻底打破 10 ...

势银咨询： 势银咨询顾问服务 重要会议： 2025势银（第五届）光刻材料产业大会（ 7月8日-10日，安徽·合肥） 点此报名 "宁波膜智信息科技有限公司"为势银（TrendBank）唯一工商注册实体及收款账户 势银研究： 势银产业研究服务 势银数据： 势银数据产品服务 添加文末微信，加 光刻胶 群 5月19日，日本材料巨头旭化成（Asahi Kasei）向部分客户发出供应调整通知，将收紧其核心产品 PSPI（商品名PIMEL）的供应。5月26日，旭化成再次传出重磅消息，对 PSPI实施断供。供应决策 一调再调的背后，是AI算力需求"野蛮生长"与有限产能之间的激烈矛盾。 一直以来，旭化成稳坐全球PSPI领域头把交椅，凭借深厚技术积累与长期市场耕耘，Pimel系列感 光材料在半导体封装领域长期独占鳌头，已然成为全球先进封装产业链运转不可或缺的关键一环。 因此，断供事件犹如一记重锤，对全球半导体产业链造成连锁冲击，让台积电、三星、盛合晶微等 半导体头部企业猝不及防，陷入材料供应短缺的困境，生产计划面临严重冲击，甚至有被迫停滞的 风险。 PSPI：撑起高端制造的"隐形支柱" 封装材料PSPI（Photosensiti ...

半导体业界流传日本化工巨头旭化成（Asahi KASEI）对客户发出的通知，提到因该公司产能无法跟上 市场需求，将对部分客户断供先进封装关键耗材感光型聚醯亚胺（PSPI），业界忧心恐导致AI断链危 机一触即发。 先进封装爆红，三星、英特尔、日月光投控、群创等大厂也积极抢进，进一步消耗PSPI产能。随着旭化 成对部份客户断供，业界忧心AI断链危机一触即发。 对于相关消息，至昨（26）日截稿前，台积电未回应。业界分析，台积电是全球晶圆代工龙头，应会获 得旭化成优先供货，研判对台积电影响不大。不过，对正积极强化先进封装能量日月光投控而言，旭化 成PSPI供货不顺，可能会打乱原先集团布局规划。惟日月光投控对此不予回应。 日月光投控内部规划，目标2025年CoWoS先进封装月产可达1万片，力拚今年相关业绩倍增至10亿美元 以上。 业界人士说，旭化成的PSPI材料，在半导体封装领域具有关键应用价值，并广获半导体指标厂采用，主 要用于元件表面保护层、凸块钝化层及RDL绝缘层，在晶圆级封装（WLP）制程中，晶圆表面钝化层 及RDL重布线层介质制造需依赖光敏绝缘材料，由于PSPI的独特优点在于兼具光敏特性与绝缘性能，可 显著简 ...

Summary of Conference Call for Aisen Co., Ltd. Industry Overview - The focus for investment this year (2025) is on self-sufficiency, particularly in the equipment and materials sectors, with domestic companies actively replacing foreign products [2][3] - The advanced packaging sector is trending towards higher integration and heterogeneous integration, with 2.5D and 3D packaging becoming key directions for GPU and AI chip development [2][4] Company Insights - Aisen Co., Ltd. has launched mass production of its positive DNQ series photoresist products, with a high market share expectation, while the negative acrylic series holds about a low double-digit percentage [2][6] - The company is conducting chemical amplification RDL photoresist tests, with client validation expected in the second half of the year, aiming for a comprehensive product layout [2][6] - Aisen's positive DNQ and negative acrylic series have gained market share in the domestic advanced packaging sector, which primarily uses JSR's post-film revival photoresist [2][7] Market Dynamics - The HBM memory market is currently dominated by international giants, but domestic companies are gradually entering this space [2][7] - Due to international political factors, the supply of HPV3 and subsequent products is limited, necessitating independent development of related technologies in China [2][8] - The TSV (Through-Silicon Via) technology is crucial in HBM structures, and Aisen is developing TSV photoresist and high-speed copper plating products [2][9] Product Development and Strategy - Aisen is focusing on developing new PSPI materials to meet the diverse needs of advanced packaging, with plans to become a leading supplier in this area within two to three years [2][4][14] - The company has established a strategic partnership with Shenghe Jingwei, focusing on electroplating and photoresist products, with significant sales growth expected [2][26] - Aisen's business performance in the advanced packaging sector is projected to grow rapidly, with a target of achieving significant sales in the wafer and advanced packaging fields [2][14][31] Challenges and Opportunities - The ongoing trade tariff war has increased material procurement costs for several packaging and testing companies, prompting a shift towards domestic materials [2][33] - The domestic PSPI market is still in its infancy, with a market size of approximately 1.5 billion RMB, and Aisen is working to increase its market share through product development and client validation [2][17][22] - The company is addressing supply chain challenges by developing multiple alternative solutions to mitigate reliance on single products [2][19] Future Outlook - Aisen anticipates structural growth driven by increasing demand from domestic clients, particularly in the HBM sector, and plans to expand its product offerings to meet market needs [2][28] - The company aims to enhance its domestic replacement rate and market share through improved risk control and technology advancements [2][25]

Core Viewpoint - Xiamen Hengkang New Materials Technology Co., Ltd. (referred to as "Hengkang New Materials") has submitted a new version of its prospectus to the Shanghai Stock Exchange and responded to the first round of inquiries regarding its planned IPO on the Sci-Tech Innovation Board [1][3]. Group 1: IPO and Fundraising - Hengkang New Materials initially planned to raise 1.2 billion yuan for projects including the second phase of integrated circuit precursors, SiARC development and industrialization, and advanced materials for integrated circuits. However, the total fundraising amount has been reduced to 1.007 billion yuan after the removal of the SiARC project from the fundraising plan [3][4]. - The company aims to allocate the raised funds primarily for the second phase of integrated circuit precursors and advanced materials projects, with total investments of approximately 5.191 billion yuan and 9.091 billion yuan respectively [4][5]. Group 2: Production Capacity and Utilization - As of the end of 2024, Hengkang New Materials operates several production lines, including 7 SOC lines and 16 BARC lines, but the capacity utilization rates remain low. For instance, the utilization rates for SOC, BARC, KrF, i-Line, and TEOS were approximately 57.42%, 21.43%, 17.55%, 46.67%, and 46.47% respectively in 2024 [6][7]. - The company has acknowledged that despite low utilization rates, it still seeks to expand production capacity through fundraising [6]. Group 3: Financial Performance - Hengkang New Materials reported revenues of approximately 322 million yuan, 368 million yuan, and 548 million yuan for the years 2022, 2023, and 2024 respectively, with net profits of approximately 99.73 million yuan, 89.76 million yuan, and 96.91 million yuan during the same periods [9]. - The total assets of the company reached approximately 2.645 billion yuan by the end of 2024, with a debt-to-asset ratio of 43.26% [10]. Group 4: Cash Flow and Funding Management - The company has a cash balance of approximately 291 million yuan and short-term borrowings of about 400 million yuan as of the end of 2024. It anticipates a funding gap of approximately 1.628 billion yuan over the next three years [8][12]. - Hengkang New Materials has indicated that the scale of its fundraising is reasonable, as only 5.31% of the funds will be allocated for R&D and working capital [8]. Group 5: Governance and Management - The chairman and general manager, Yi Rongkun, is the controlling shareholder, holding 19.52% of the voting rights directly and an additional 16.13% indirectly through related entities [17]. - The company has faced inquiries from the Shanghai Stock Exchange regarding the governance structure and the roles of key management personnel, particularly concerning the involvement of family members in decision-making processes [18].